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Human natural killer (NK) cells are considered professional cytotoxic cells that are integrated into the effector
branch of innate immunity during antiviral and antitumoral responses. The purpose of this study was to examine
the peripheral distribution and expression of NK cell activation receptors from the fresh peripheral blood
mononuclear cells of 30 breast cancer patients prior to any form of treatment (including surgery, chemotherapy,
and radiotherapy), 10 benign breast pathology patients, and 24 control individuals. CD3−CD56dimCD16bright NK
cells (CD56dim NK) and CD3−CD56brightCD16dim/− NK cells (CD56bright NK) were identified using flow cytometry.
The circulating counts of CD56dim and CD56bright NK cells were not significantly different between the groups
evaluated, nor were the counts of other leukocyte subsets between the breast cancer patients and benign breast
pathology patients. However, in CD56dim NK cells, NKp44 expressionwas higher in breast cancer patients (P= .0302),
whereas NKp30 (P= .0005), NKp46 (P= .0298), and NKG2D (P= .0005) expression was lower with respect to healthy
donors. In CD56bright NK cells, NKp30 (P= .0007), NKp46 (P= .0012), and NKG2D (P= .0069) expressionwas lower in
breast cancer patients compared with control group. Only NKG2D in CD56bright NK cells (P= .0208) and CD56dim NK
cells (P = .0439) showed difference between benign breast pathology and breast cancer patients. Collectively, the
current study showed phenotypic alterations in activation receptors on CD56dim and CD56bright NK cells, suggesting
that breast cancer patients have decreased NK cell cytotoxicity.
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Breast cancer is a highly heterogeneous disease presenting a broad
range of molecular and clinical characteristics and is the most
diagnosed malignancy in women worldwide [1]. There is strong
evidence that the innate and adaptive immune response plays a role in
tumor growth and progression. An effective immune response may
lead to recognition of tumor cells, resulting in their eradication.
However, due to their genetically unstable nature, tumor cells may
arise with properties that enable them to escape from the immune
system [2,3].
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associated with the presence of higher numbers of tumor-infiltrating
lymphocytes since 1922 [4]. Early studies identified tumor-infiltrating
lymphocytes in breast cancer as a lymphocyte population comprising
mainly cytotoxic T cells, together with varying proportions of helper
T cells and B cells, and rare natural killer (NK) cells [5,6].
NK cells are important components of the innate immune system and
play a central role in the defense against viral infections, as well as in
tumor surveillance [7]. NK cells are also associated with the adaptive
immune response through the production of cytokines. In humans, NK
cells are usually defined as CD3−CD56+[8] and can be further
subdivided based on CD56 expression. CD56dimCD16bright (CD56dim
NK) cells and CD56brightCD16dim/− (CD56bright NK) cells differ in
terms of phenotype, effector function, and tissue localization.
CD56dim NK cells constitute the majority (90%) of peripheral
blood NK cells and express high levels of the low-affinity Fcγ receptor
CD16, through which they can exert antibody-dependent
cell-mediated cytotoxicity [9,10]. Engagement of CD16 is sufficient
to induce interferon-gamma (IFN-γ) and tumor necrosis factor
(TNF) secretion, in addition to chemokine secretion. NK cell
function is controlled by the integration of signals from various
activation and inhibitory receptors, which bind to components of
pathogens and tumoral antigens [11–13]. The most potent activation
receptors of NK cells are the antibody-dependent cell-mediated
cytotoxicity–mediating molecule CD16 and natural killer group 2D
(NKG2D) [10–13]. Moreover, NK cells mediate “natural cytotoxicity”
via a set of activating natural cytotoxicity receptors (e.g., NKp30,
NKp44, and NKp46), which recognize their ligands in tumor or
virus-infected cells [9,10,14].
In contrast, CD56bright NK cells are poorly cytotoxic and are major
cytokine producers that respond to cytokines such as IL-12, IL-18, or
IL-15. Although CD56bright NK cells constitute the minority of
peripheral blood NK cells, they represent the large majority of NK
cells in secondary lymphoid organs [9,10]. It remains unclear whether
the CD56bright NK subsets are precursors of CD56dim NK cells or
whether the CD56bright population represents an activated or
differentiated CD56dim NK cell subtype.
Breast tumors act systemically to sustain cancer progression,
affecting the physiological processes in the host and triggering
responses in the peripheral blood cells [15]. The peripheral blood
cells monitor the body's physiological status and modify their
immunophenotype in response to pathological changes [16–19].
Due to its easy access, peripheral blood constitutes an interesting
source to measure functional competence of immune cell subsets.
Immune cell dysfunctions were found in peripheral blood from
breast cancer patients detected through whole blood multiparametric
flow cytometry assay [20]. Hence, the aim of this study was to
evaluate the frequency of CD56dim NK cells and CD56bright NK
cells in the peripheral blood of women with breast cancer, women
with benign breast pathology, and healthy controls.
Materials and Methods
Patients and Healthy Donors
A group of 64 women was studied. Study participants were enrolled at
the Department of Oncology of the Hospital Juárez de México. All
women were informed of the goal of the study and provided informed
consent. The breast cancer group comprised women matching the
disease's diagnostic criteria after physical exams; mammograms;ultrasounds; blood chemistry studies; biopsies; and, in some cases,
magnetic resonance imaging. The noncancerous (benign) breast tumor
group comprised women matching the diagnostic criteria of fibroade-
noma after physical exams, mammograms, ultrasounds, blood chemistry
studies, and biopsies. The exclusion criteria for the studied groups
included concurrent medical problems that may cause disordered
inflammatory responses, such as diabetes and autoimmune diseases.
Twenty-four blood samples from healthy women were also collected.
Blood Sample Collection
Four milliliters of peripheral blood were collected into EDTA tubes
(Becton Dickinson and Company, Franklin Lakes, NJ) from the
antecubital vein of each subject. All blood samples were processed within
2 hours after sampling. Peripheral blood mononuclear cells (PBMCs)
were isolated using the density centrifugation technique (Ficoll-Paque
PLUS; Amersham Biosciences, Uppsala, Sweden) and then immediately
utilized. Total circulating counts for leukocytes, lymphocytes, mono-
cytes, and neutrophils were determined based on 2 ml of EDTA-treated
blood using a Siemens high-volume hematology analyzer with an ADVIA
2120i System with Autoslide (Siemens AG, Munich, Germany).
Flow Cytometry Analyses
To identify NK cell subsets, PBMCs were stained for surface antigens
with a phycoerythrin-conjugated mAb specific for NKp44 (BD
Pharmingen, San Jose, CA; clone p44-8), phycoerythrin-conjugated
mAb specific for NKp46 (BD Pharmingen; clone 9E2/NKp46), Alexa
Fluor 647–conjugated mAb specific for NKp30 (BD Pharmingen; clone
p30-15), Allophycocyanin (APC)-conjugated mAb specific for NKG2D
(BD Pharmingen; clone 1D11), allophycocyanin-Hilite 7 (APC-H7)–
conjugated mAb specific for CD3 (BD Pharmingen; clone SK3), violet
450 (V450)–conjugated mAb specific for CD56 (BD Horizon; clone
B159), and violet 500 (V500)–conjugated mAb specific for CD16 (BD
Horizon; clone 3G8) in accordance with the manufacturer's instructions.
Briefly, 1 × 106 PBMCs were stained with fluorochrome-conjugated
mAbs specific for cell surface antigenmarkers for 20minutes in the dark at
4°C. After initial staining, the cells were washed twice using
phosphate-buffered saline at pH 7.4, followed by surface marker fixation.
The negative control samples were incubated with isotype-matched
antibodies. After incubation, the cells were resuspended in 200 μl of
phosphate-buffered saline for subsequent flow cytometry analysis using a
FACS Verse flow cytometer (BD Biosciences, San Jose, CA). The
resultant data were analyzed using FlowJo software V10.0.8 (Tree Star,
San Carlos, CA).
Lymphocytes were defined and separately gated on the basis of
forward light scatter and side light scatter for further analysis.
Furthermore, the proportions of the major subsets of cells stained by
antibodies were determined using gating of individual areas based on
the first-gated lymphocytes. NK cells were divided into two subsets
on the basis of CD56 surface density. CD3−CD56dimCD16bright NK
cell (CD56dim NK) and CD3−CD56brightCD16dim/− NK cell
(CD56bright NK) subsets were distinguished using gated flow
cytometric analyses (Figure 1). Absolute cell counts were derived by
multiplying the percentage of a given cell subset by the total
lymphocyte concentration found in the peripheral blood. The results
were expressed as the percentage of cells in a gated CD3− region.
Ethics Statement
The Hospital Juarez of Mexico Scientific Research Committee
(composed of Scientific, Ethics, and Bio-security Committees) approved
the project (project number: HJM 2321/14B), and the protocols that
Figure 1. Gating strategies for flow cytometry analysis of CD56dim NK and CD56bright NK cells. Representative gating strategy of
peripheral blood breast cancer patient. PBMCs were isolated using the density centrifugation technique. To identify NK cell subsets,
PBMCs were stained for surface antigens with APC-H7–conjugated mAb specific for CD3, V450-conjugated mAb specific for CD56, and
V500-conjugated mAb specific for CD16. Dot plot CD56 V450 versus CD16 V500 graph, lower box: CD56dim NK cell subset (CD3− CD16+
CD56dim), upper box: CD56bright NK cell subset (CD3− CD16+/− CD56bright).
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Helsinki. All enrolled individuals provided written informed consent.
Statistics
The distribution of the data was tested for normality using the
Kolmogorov-Smirnov test. Student's t test was used for continuous
variables that were normally distributed, and the nonparametric
Mann-Whitney U test was used to compare cell percentages betweenTable 1. Sociodemographic Characteristics of the Study Groups
Group Healthy Donors (n = 24) Noncancero
Age, mean ± SD 49.6 ± 13.4 44.8 ± 12.4
First menstruation age, mean ± SD 12.5 ± 1.4 12.4 ± 0.8
Family history of breast cancer 12.5% (n = 3) 10% (n = 1
Use of oral contraceptives 29.2% (n = 7) 60% (n = 6
First pregnancy age, mean ± SD 20.9 ± 4.7 16.5 ± 1.2
Number of pregnancies, mean ± SD 3.1 ± 1.4 2.3 ± 1.3
Breastfeeding 95.8% (n = 23) 100% (n =
Obesity 25% (n = 6) 30% (n = 3
Alcoholism 20.8% (n = 5) 20% (n = 2
Smokers 12.5% (n = 3) 20% (n = 2
Notes: Sociodemographic data were obtained by personal questionnaires. P value is from the Mann-Wh
variables between breast cancer versus healthy donors (a) and breast cancer versus noncancerous breagroups. P values b.05 were considered significant. Statistical analyses
were performed usingGraphPadPrism version 5.0 (GraphPad Software,
La Jolla, CA).
Results
Thirty breast cancer patients ranging from 27 to 84 years of age and
10 noncancerous breast tumor patients ranging from 24 to 69 years of
age were analyzed between April 2014 and March 2016, as were 24us Breast Tumor (n = 10) Breast Cancer (n = 30) P Value
55.3 ± 13.5 P = .062aP = .069b
12.8 ± 1.6 P = .618aP = .577b
) 16.7% (n = 5) P = .72aP = 1.0b
) 46.7% (n = 14) P = .263aP = .716b
23.2 ± 3.2 P = .099aP b .0001b
3.5 ± 1.6 P = .015aP = .039b
10) 100% (n = 30) P = 1.0aP = 1.0b
) 56.7% (n = 17) P = .027aP = .273b
) 6.7% (n = 2) P = .231aP = .256b
) 23.3% (n = 7) P = .483aP = 1.0b
itney U test for comparisons of means and from Fisher's exact test for comparisons of the categorical
st tumor (b).
Table 2. Breast Cancer Tumor Characteristics
Characteristics
Tumor size (cm), mean ± SD 4.43 ± 2.02
Tumor status
T1 16.6% (n = 5)
T2 36.6% (n = 11)
T3/4 46.6% (n = 14)
Stage of breast cancer
Stage IIA 23% (n = 7)
Stage IIB 27% (n = 8)
Stage IIIA 27% (n = 8)
Stage IIIB 23% (n = 7)
Estrogen receptors
Positive 60% (n = 18)
Negative 40% (n = 12)
Progesterone receptors
Positive 50% (n = 15)
Negative 50% (n = 15)
HER2/Neu
Positive 53% (n = 16)
Negative 47% (n = 14)
Note: The presence of estrogen receptors, progesterone receptor, and HER2/Neu was detected by
immunohistochemistry.
Table 3. Absolute Numbers and Percentages of White Blood Cells of Breast Cancer and
Noncancerous Breast Tumor Patients
Group Noncancerous Breast
Tumor (n = 10)
Breast Cancer (n = 30) P Value
(×103/μl) (%) (×103/μl) (%)
Lymphocytes 2.3 ± 0.7 28.2 ± 5.2 2.2 ± 0.6 28.5 ± 7.8 P = .684aP = .912b
Monocytes 0.4 ± 0.1 4.9 ± 1.1 0.4 ± 0.1 5.4 ± 1.1 P = .416aP = .100b
Eosinophils 0.2 ± 0.1 2.0 ± 0.9 0.2 ± 0.1 2.1 ± 1.4 P = .648aP = .753b
Neutrophils 5.2 ± 1.3 62 ± 5.4 4.6 ± 1.4 59.5 ± 10.5 P = .229aP = .390b
Basophils 0.04 ± 0.02 0.5 ± 0.3 0.05 ± 0.03 0.7 ± 0.4 P = .161aP = .144b
Notes: Data were obtained by Siemens high-volume hematology analyzer with an ADVIA 2120i
System. Data are presented as absolute number (×103/μl) and percentages (%) of peripheral blood
leukocytes. P value is from the Mann-Whitney U test for comparisons of means of absolute number
(a) and percentage (b) of cells between breast cancer versus noncancerous breast tumor.
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86 years of age. No significant differences were found in age, first
menstruation age, family history of breast cancer, use of oral
contraceptives, maternal lactancy, consumption of alcoholic bever-
ages, and tobacco use among the groups studied. The group of breast
cancer patients showed higher first pregnancy age and number of
pregnancies, as well as greater presence of obesity (Table 1).
The main characteristics of the 4970 eligible cases included in the
analysis are summarized in Table 1.
In this study, there were 30 patients with histologically confirmed
breast cancer; the mean age at diagnosis was 55.3 ± 13.5 years. The
tumor size ranged from 2 to 10 cm in diameter with an average
(mean) of 4.43 ± 2.02 cm. Test for hormone receptor expression
revealed that 18 patients were ER positive, 15 patients were PR
positive, and 16 patients were HER2/Neu positive (Table 2).
There were no significant differences in the absolute numbers or
percentages of white blood cells, CD4+T cells, CD8+T cells, B cells, NK
cells,monocytes, eosinophils, neutrophils, and basophils (Tables 3 and 4).
Frequencies of Peripheral NK Cell Subsets
The group of breast cancer patients showed 90.98% (78.0-98.9) of
CD56dim NK cells, whereas the healthy-donors group has 91.96%
(86.3-97.1) of CD56dim NK cells in PBMC; there was no significant
difference P = .6259. In the noncancerous group, the percentage of
CD56dim NK cells was 93.95% (91.4-96.1); compared with the
breast cancer patients, there was no significant difference (P = .3329)
(Figure 2A).
With respect to the percentage of CD56bright NK cells in PBMC,
the breast cancer patients showed 9.02% (1.1-2.2) and the
healthy-donors group had 8.04% (2.9-13.6); these differences were
not significant (P = .7277). The noncancerous group showed 6.05%
(3.9-8.6) of CD56bright NK cells in PBMC; compared with healthy
donors and breast cancer patients, there were no significant
differences (P = .084 and P = .3329, respectively) (Figure 2B).
Expression of NK Cell Activating Markers
To determine whether breast cancer modulates the expression of the
main NK cell activating receptors involved in tumor cell killing, we
evaluated the presence of NKG2D, NKp46, Nkp44, and NKp30 onperipheral bloodCD56dim NK andCD56bright NK cells in breast cancer
patients, noncancerous breast tumor patients, and healthy donors
women. Our results showed that on CD56dim NK cells, NKp44
expression determined bymean fluorescence intensity by flow cytometry
was significantly higher in women with breast cancer than in healthy
donors (P = .0302), although no differences were found between the
healthy control group and noncancerous breast tumor group.
Interestingly, no differences were found in NKp44 expression on
CD56bright cells between any of the groups studied (Figure 3A).
We found that breast cancer patients showed decreased NKG2D
expression in both NK cell subsets compared with both the healthy
control group (CD56dim NK, P = .0001; CD56bright, P = .0001) and
the noncancerous breast tumor group (CD56dim NK, P = .0005;
CD56bright, P = .0069). Furthermore, in both NK cell subsets,
noncancerous breast tumor patients showed decreased NKG2D
expression compared with the control group (CD56dim NK, P =
.0005; CD56bright, P = .0069) and increased NKG2D expression
compared with breast cancer patients (CD56dim NK, P = .0439;
CD56bright, P = .0208) (Figure 3B).
Finally, our analysis indicated decreased expression of NKp30 on
NK cell subsets in breast cancer patients (CD56dim NK, P = .0001;
CD56bright, P = .0001) and noncancerous breast tumor patients
(CD56dim NK, P = .0005; CD56bright, P = .0007) compared with
healthy controls group (Figure 3C). Furthermore, the expression of
NKp46 on NK cell subsets showed the same pattern (breast cancer
versus control: CD56dim NK, P = .0001; CD56bright, P = .0001;
noncancerous versus control: CD56dim NK, P = .0298; CD56bright,
P = .0120) (Figure 3D).
Discussion
There is ample evidence that NK immune surveillance is of crucial
importance for solid tumors [21]. Detecting subsets of immune cells
may be one beneficial way to understand immune function, which may
assist in clinical diagnoses of diseases and provide evidence for disease
pathogenesis, course, and prognosis [22]. We implemented this study
using peripheral blood in an attempt to assess immune function
variation by measuring NK cell subsets. An important strength of our
study was the use of breast cancer patient blood samples that had been
taken prior to any form of treatment, including surgery, chemotherapy,
and radiotherapy. This allowed us to examine differences in host
immune status without the confounding influence of treatment effects.
Our results did not show any significant changes in NK cell
numbers and frequency in peripheral blood of untreated breast cancer
Table 4. Absolute Numbers and Percentages of T Cells, B Cells, and NK Cells of the Study Groups
Group Healthy Donors (n = 24) Noncancerous Breast
Tumor (n = 10)
Breast Cancer (n = 30) P Value
(×103/μl) (%) (×103/μl) (%) (×103/μl) (%)
T cells (CD3+/CD45+) 1.2 ± 0.4 19.2 ± 1.7 1.6 ± 0.5 19.5 ± 3.6 1.5 ± 0.4 19.8 ± 5.5 P = .0045aP = .8027bP = .2883cP = .7311d
CD8+ T cells 0.4 ± 0.1 30.6 ± 4.9 0.56 ± 0.16 35.2 ± 3.2 0.57 ± 0.17 37.4 ± 2.9 P b .0001aP = .6846bP b .0001cP = .0676d
CD4+ T cells 0.6 ± 0.2 53.3 ± 4.9 0.89 ± 0.27 54.8 ± 5.1 0.82 ± 0.24 54.2 ± 5.1 P = .0021aP = .5953bP = .8074cP = .3903d
CD19+ B cells (CD3−/CD45+) 0.3 ± 0.1 5.2 ± 1.6 0.4 ± 0.13 4.8 ± 0.9 0.37 ± 0.14 4.9 ± 1.8 P = .1635aP = .5844bP = .4805cP = .9378d
CD16+CD56+ total NK cell (CD3-CD19/CD45+) 0.2 ± 0.1 3.4 ± 1.3 0.27 ± 0.1 3.3 ± 0.8 0.24 ± 0.09 3.2 ± 1.1 P = .1337aP = .3902bP = .5714cP = .6732d
Notes: T cells, B cells, and NK cells are presented as absolute number (×103/μl) and percentages (%) of peripheral blood leukocytes. CD8+ T cells and CD4+ T cells are presented as percentages (%) of
T cells. P value is from the Mann-Whitney U test for comparisons of means of absolute number (a) and percentage (c) of cells between breast cancer versus healthy donors and absolute number (b) and
percentage (d) of cells between noncancerous breast tumor versus healthy donors.
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alteration in NK cell numbers in breast cancer based on expression of
CD56 and CD16 [23]. However, another group showed an increased
percentage of CD3−CD56+ cells in peripheral blood of breast cancer
patients [24,25]. These discrepancies could be attributed to the fact
that NK cells were characterized with only two markers (CD3 and
CD56) and patients were receiving adjuvant tamoxifen therapy at the
time of testing, which has been suggested to have immunomodulatory
effects [26].
It was reported that malignant breast tissues had less CD56dimCD16+
cells than healthy mammary tissues; furthermore, breast tissues had
increased infiltration of CD56brightCD16 NK cells [25,27,28], and this
would indicate that tumor-infiltrating NK cells had poor cytotoxic
capacity. However, this phenomenon is not reflected by the frequencies
NK cell subsets in peripheral blood, suggesting that altered NK cell
subset numbers depended on the tumor microenvironment. But we
found differences in the expression of natural cytotoxicity receptors and
NKG2D on CD56dim NK and CD56bright cells; it could be indicate
that NK cells gain immunoregulatory properties which may partly
explain the low cytotoxic functions of NK cells in breast cancer reported
earlier [23,28,29].
NKp44 expression is restricted to activated NK cells capable of
initiating an immediate cytotoxic response [30].NKp44 is implicated in
the recognition and killing of numerous types of cancer, includingFigure 2. Frequencies of CD56dim (CD3− CD16+ CD56dim) NK and C
subset from total NK cells of 24 healthy donors, 10 noncancerous
surface antigens with APC-H7–conjugated mAb specific for CD3, V4
specific for CD16. There were no significant differences between theneuroblastoma; choriocarcinoma; pancreatic adenocarcinoma; lung
adenocarcinoma; colon, cervix, and hepatocellular carcinoma; and
prostate and breast carcinoma [31–33]. Our result showed upregulated
levels of NKP44 on CD56dimm NK cells, which would indicate a good
outcome in killing tumor cells, but tumors may also downregulate
NKp44 surface expression by shedding soluble MHC class I
chain-related molecules or by releasing indoleamine 2,3-dioxygenase
and prostaglandin E2 [34,35]. Additionally, tumor cells may induce
expression of exosomal proliferating cell nuclear antigen when
physically contacted by NKp44 expressing NK cells to inhibit NK
cell effector function [36].
Interestingly, the cytoplasmic tail of NKp44 contains a tyrosine
motif resembling an ITIM; contrary to initial reports, this motif is
functional and inhibits the release of IFN-γ [30,36,37]. NKp44
surface expression is dependent on its association with the ITAM
containing DAP12 accessory protein, which results in the release of
cytotoxic agents, TNF, and IFN-γ [37]. We highlight the importance
of further studies for unraveling the precise signaling of NKp33 in
breast cancer patients.
High expression of NKG2D ligands has been found in various
types of tumors, such as ovarian cancer, colorectal cancer, and breast
cancer [38–40]. Expression of NKG2D ligands may induce an
immune response by binding to the NKG2D receptor, which is
present in NK cells [41]. The downregulation or complete knockoutD56bright (CD3− CD16+/− CD56bright) NK cells. Percentage of each
patients, and 30 breast cancer patients. PBMCs were stained for
50-conjugated mAb specific for CD56, and V500-conjugated mAb
groups.
Figure 3. Phenotype analysis of activation receptors on peripheral CD56dim (CD3− CD16+ CD56dim) NK and CD56bright (CD3− CD16+/−
CD56bright) NK cells. Box plots show expression of cytotoxicity activation markers of 24 healthy donors, 10 noncancerous patients, and 30
breast cancer patients. PBMCs were stained with mAb. Each box plot has a representative histogram of the activation receptor on CD56dim
andCD56bright NK cells; the threshold between negative and positivewas defined by the fluorescenceminus one (FMO)method (dotted line).
(A)MFI ofNKp44, (B)MFI of C-type lectin receptorNKG2D, (C)MFI ofNKp30, and (D)MFI ofNKp46 onCD56dim NKcell and CD56bright NK cell.
Analysis was performed using the Mann-Whitney U test. P values of significant differences between the groups were written.
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tumor cells, higher expression levels of NKG2D ligands, and an
increased incidence of certain tumors [42,43]. We found that breastcancer patients showed decreased expression of NKG2D in both NK
cell subsets, which may indicate a possible evasion mechanism for
tumor cells to prevent NK lysis (Figure 3A).
390 NK cell activation receptors in breast cancer Nieto-Velázquez et al. Translational Oncology Vol. 9, No. 5, 2016In contrast to the knowledge on the regulation of NKG2D and
NKp40 in tumor immunology, the understanding of the natural
cytotoxicity receptors NKp46 and NKp30 and their ligands remains
limited. A recent study revealed that neuroblastoma tumor cell–derived
factors caused downregulation of NKp30 in a TGF-β1–dependent
manner [44] and that inhibitory NKp30 splice variants were identified
that affect the prognosis of gastrointestinal sarcoma [45]. Our results
showed that breast cancer patients and patients with benign tumors had
decreased NKp30 and Nkp46 expression on peripheral CD56dim NK
and CD56bright NK cells, which suggests that malignant cells bypass
NK surveillance by downregulating these receptors. Future studies will
be necessary to dissect the effects of expression of the immunosuppres-
sive NKp30C isoform and the activating isoforms NKp30A/B in breast
cancer patients.
Conclusions
The results of this study indicate that breast cancer patients have
phenotypically altered activation receptors on CD56dim and CD56bright
NK cells, suggesting that these patients have decreased NK cell
cytotoxicity. Furthermore, this study provides further evidence that NK
cells play an important role in breast cancer.
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